Identification
- Generic Name
- Ciliary neurotrophic factor
- DrugBank Accession Number
- DB05344
- Background
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF).2 It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor
- CILIARY NEUROTROPHIC FACTOR
- Ciliary neurotrophic factor - Neurotech
- CILIARY NEUROTROPHIC FACTOR (HUMAN)
- Ciliary neurotrophic factor implant - Neurotech
- HUMAN CILIARY NEUROTROPHIC FACTOR
- HUMAN CNTF
- NT 501
- NT-501
- NT501
Pharmacology
- Indication
Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
NT-501 is an intraocular, cell containing polymer implant designed to provide the continuous, long-term release of the therapeutic protein, Ciliary Neurotrophic Factor (CNTF), directly into the back of the eye by means of the Company's proprietary Encapsulated Cell Technology (ECT).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- CR102F038W
- CAS number
- 133423-39-9
References
- General References
- Thanos CG, Bell WJ, O'Rourke P, Kauper K, Sherman S, Stabila P, Tao W: Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng. 2004 Nov-Dec;10(11-12):1617-22. [Article]
- BioSpace: Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors [Link]
- External Links
- PubChem Substance
- 347910092
- Wikipedia
- Ciliary_neurotrophic_factor
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Macular Telangiectasia Type 2 2 2 Active Not Recruiting Treatment Glaucoma 1 2 Completed Treatment Idiopathic Juxtafoveal Telangiectasia 1 2 Completed Treatment Macular Degeneration 1 2 Completed Treatment Macular Telangiectasia Type 2 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at November 18, 2007 18:24 / Updated at October 05, 2023 17:34